Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Complying with REMS Training and Documentation Requirements
Michael Singel, PharmD, discusses the logistics of complying with the Risk Evaluation and Mitigation Strategy program for bispecific antibodies at his institution and addresses training and documentation requirements.
EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment
EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma
EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma
EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma
EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma
EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma
EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
Now Viewing
EP: 11.Complying with REMS Training and Documentation Requirements
EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
EP: 13.Unmet Needs in Multiple Myeloma Care
EP: 14.Treatment Sequencing and Combination Therapies for MM
EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM
EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care
EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics
EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting
EP: 21.Team Approach to Meeting REMS Program Requirements
EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies
EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma
Recent Videos
Related Content
